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We have studied the global frequency distributions of 10 single nucleotide
polymorphisms (SNPs) across 132kb of CYP2C8 and CYP2C9 in B2500
individuals representing 45 populations. Five of the SNPs were in noncoding
sequences; the other five involved the more common missense variants (four
in CYP2C8, one in CYP2C9) that change amino acids in the gene products.
One haplotype containing two CYP2C8 coding variants and one CYP2C9
coding variant reaches an average frequency of 10% in Europe; a set of
haplotypes with a different CYP2C8 coding variant reaches 17% in Africa. In
both cases these haplotypes are found in other regions of the world at o1%.
This considerable geographic variation in haplotype frequencies impacts the
interpretation of CYP2C8/CYP2C9 association studies, and has pharmacoge-
nomic implications for drug interactions.
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Introduction
The CYP2C8 and CYP2C9 enzymes are members of the cytochrome-P450 CYP2C
subfamily of enzymes that are responsible for metabolizing approximately 20%
of pharmaceutical drugs used today. CYP2C8 metabolizes various endogenous
compounds including arachidonic acid, retinoic acid, and therapeutic drugs such
as the widely used chemotherapeutic agent paclitaxel.
1 CYP2C8 and CYP2C9
activities overlap in that both enzymes can metabolize arachidonic acid, several
nonsteroidal anti-inflammatory drugs, retinoic acid and others. CYP2C9
separately has been implicated in the metabolism of warfarin, celecoxib,
nateglinide and others.
2,3
Both CYP2C8 and CYP2C9, the genes coding for these enzymes, are known to be
p o l y m o r p h i c( f i r s tr e p o r t e db yD a i
4 and Stubbins
5), and previously published data
suggest frequencies of the variant alleles differ among ethnic populations.
6 This
genetic variation has been shown to have pharmacological implications. The
specific functional consequences of the derived variants depend on the substrate.
For CYP2C8 264Met, the activity ranges from 0 to 15% compared to 264Ile,
7 and for
269Phe the activity for paclitaxel is 50% that of 269Ile.
4 At CYP2C9, activity of
144Cys ranges from 10 to 90% of the activity of 144Arg.
2 The derived CYP2C8
variants, 139Lys and 399Arg, which occur together on the same molecule, produce
an enzyme with 15–40% of activity compared to the ancestral form,
4 depending on
substrate. Clearer understanding of the associations can move us a step forward
toward individualized drug administration and dosing.
8 The two genes are adjacent
and within a genomic segment of B130kb on chromosome 10.
Several studies suggest a relationship between CYP2C8 variants, the metabolic
index of paclitaxel and drug-related toxicities.
4,9–13 Though many of those
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pharmacokinetics, some found no association with
specific functional variants at CYP2C8, arguing that those
variants were not responsible for the variation. However,
other variants at CYP2C8 do seem relevant.
13 In addition,
ethnic distributions of the CYP2C8 polymorphisms
suggest that whichever variant alleles affect paclitaxel
metabolism may be more common in a particular ethnic
group.
14–16 This observation suggests one explanation for
varying degrees of toxicities from therapeutic drugs, not
limited to paclitaxel, seen in patients of different ethnic
ancestries.
17–22 To test the hypothesis that CYP2C8 variation
is related to paclitaxel metabolism and toxicity, we are
conducting a clinical trial testing the effects of CYP2C8
haplotypes on drug-related toxicities from paclitaxel in
different ethnic groups of breast cancer patients. In design-
ing and conducting a genotype–phenotype association
study that can also address interethnic genetic variation,
an accurate characterization of global variation in target
genes is critical. As such data for CYP2C8 haplotypes are
scanty, we have undertaken to assemble the necessary
dataset. As linkage disequilibrium (LD) between CYP2C8
and CYP2C9 has been reported
23 and can be seen in
HapMap data, we included some CYP2C9 polymorphisms
in this initial study.
Using available public databases detailing known com-
mon coding and noncoding polymorphisms, we selected
and studied 10 single nucleotide polymorphisms (SNPs) of
the CYP2C8 and CYP2C9 genes in populations around the
world (Table 1). We also estimated haplotype frequencies for
the CYP2C8–CYP2C9 region in these diverse populations. In
this paper, we present our initial data demonstrating
population-specific allele and haplotype frequencies of
CYP2C8 and CYP2C9. This unique dataset will be instru-
mental in future investigations of differences in CYP2C8-
mediated drug metabolism among ethnic populations and
in designing clinical trials to examine the putative func-
tional impact of genetic polymorphisms of CYP2C8 and
CYP2C9.
Results
CYP2C8-CYP2C9 polymorphism frequencies
Samples from B2500 individuals were typed for 10 selected
SNPs across a region of 132kb on chromosome 10 encom-
passing CYP2C8 and CYP2C9. SNPs across the CYP2C8–
CYP2C9 region showed significant allele frequency variation
among populations in different geographic regions
(Table 1; Figure 1). None of the 450 Hardy–Weinberg tests
(45 populations for 10 SNPs) was significant when multiple
testing was taken into account. Thus, our assumption that
no cryptic variation interfered with the genotyping assays
seems reasonable, though we cannot exclude rare sequence
variants that may have interfered with the TaqMan assay
resulting in a ‘null’ allele. All of the allele frequency data can
be found in ALFRED (the ALlele FREquency Database) using
the dbSNP rs# in Table 1 as a keyword. The typing of our
non-human primate samples unambiguously identified the
ancestral human sequences and was in agreement with the
data in the UCSC Genome Browser whenever primate
sequences were available.
Haplotype frequencies and linkage disequilibrium
Seventeen common haplotypes were found (Table 2).
Estimated haplotype frequencies, plotted in Figure 2,
showed that considerable geographic variation exists in
haplotype frequencies and that some of the commonly
studied functional variants exist on more than one haplo-
type. Moreover, individual haplotypes contain different
combinations of some of the functional variants. Haplotype
frequencies are available in ALFRED. There is a complex
pattern of pairwise LD that varies among populations as
Table 1 The 10 polymorphisms (SNPs) studied across CYP2C8 and CYP2C9
The amino-acid changes are indicated for those SNPs in exons. For the nonsynonymous (functional) SNPs the most closely corresponding CYPAllele designation is given
in parentheses.
TaqMan Assay ancestral Chr
Position
(build 36.1)
SNP order
in
haplotype
rs4918758 C___1329192_10 [C/T] CYP2C9 + 1 96,687,242
rs1799853 C__25625805_10 [C/T] CYP2C9 + CYP2C9 Arg144Cys
rs1934953 C____361408_10 [C/T] CYP2C8 - 3 96,787,460
rs10509681 C__25625782_20 [C/T] CYP2C8 +
Lys399Arg:
(CYP2C8*3 allele2)
rs11572103 C__30634034_10 [A/T] CYP2C8 96,808,096
Ile269Phe:
(CYP2C8*2)
rs1058930 C__25761568_20 [C/G] CYP2C8 -
-
96,808,109
Ile264Met:
(CYP2C8*4) 6
rs11572093 C___1980078_10 [C/T] CYP2C8 - 7 96,814,396
rs11572080 C__25625794_10 [C/T] CYP2C8 96,817,020
Arg139Lys:
(CYP2C8*3 allele1)
rs11572076 C__31658115_10 [C/T] CYP2C8 -
-
9 96,817,140
rs17110453 C___1980090_20 [A/C] CYP2C8 +1 0 96,819,519
alleles dbSNP gene Strand Functional SNPs
C
C
C
C
C
T
T
T
G
A
10
10
10
10
10
10
10
10
10
10
96,788,739
2 96,692,037
4
5
8
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The Pharmacogenomics Journaldifferent haplotypes become more or less frequent (data not
shown). Because of the large sample sizes studied in many
populations, and the large number of populations, we have
a clearer understanding of the genetic variation seen
previously in individual populations
24 and at each locus
independently.
25 Haplotype G, seen at moderate frequencies
(0.05–0.23) only in Europe and Southwest Asia, contains
three coding variants: CYP2C8*139Lys, CYP2C8*399Arg and
CYP2C9*144Cys. Other combinations of those variants
occur in haplotypes H and K. In Africa, the combined
frequencies of CYP2C8*269Phe-containing haplotypes B, L
and M range from 0.06 to 0.28, but these haplotypes are
virtually absent elsewhere in the world. Haplotypes C and N
have the CYP2C8*264Ile variant and occur primarily in
European populations, but always at low frequencies.
Known functional variation is vanishingly rare in Central
Asia through East Asia, the Pacific and the Americas.
Discussion
Genetic variation and cancer therapy
Genetic variation has been considered, for some time, to be
a major reason for varying susceptibility of individuals to
diseases and responses to drugs. Following the completion
of the human genome project, the field of pharmacoge-
nomics has captured the imagination of many clinical
investigators with the prospect of realizing personalized
medicine. Naturally, cancer pharmacologists have invested
significant effort and resources into investigating variation
among individuals in drug responses and toxicities to
chemotherapy agents, as anticancer agents often have a
narrow therapeutic window and consequences of subopti-
mal dosing can be detrimental. For example, the implica-
tions of variant alleles of dihydropyrimidine dehydrogenase
on toxicity of 5-fluorouracil-based agents are well described
in the literature.
26 In addition, polymorphism at CYP2D6
has a predictive value in treatment of breast cancer with
tamoxifen, a known substrate of this enzyme. Furthermore,
the observation that genetically variant UDP-glucuronosyl-
transferase 1A1 accounts for significant toxicity from
irinotecan therapy led US Food and Drug Administration
to recommend dose adjustment according to each patient’s
genomic profile.
Table 2 The haplotype compositions of the 17 common
haplotypes, color coded as in Figure 2
Haplotype
Name
SNP composition of
haplotype (5'-3')
A
B
C
D
E
F
G
C9*144Cys; C8*399Arg;
C8*139Lys
H
I
J
K
L
M
N
O
P
Q
residual
Amino Acid changes on haplotype
C8*269Phe
C8*264Ile
C9*144Cys
C8*399Arg; C8*139Lys
C8*269Phe
C8*269Phe
C8*264Ile
CCTTTGCCCC
CCCTTGCCCA
CCTTAGCCCA
CCTTTCCCCC
CCTTTGCCCA
CCTTTGTCCA
TCTTTGTCCA
CTTCTGCTCA
CTTTTGTCCA
TCCTTGCCCA
TCCTTGCCCC
TCTCTGCTCA
TCTTAGCCCA
TCTTAGCCTA
TCTTTCCCCC
TCTTTGCCCA
TCTTTGCCCC
Figure 1 A graphical depiction of the frequencies of the ancestral alleles at the 10 single nucleotide polymorphisms (SNPs) studied in the 45
populations. The figure illustrates the frequencies of these alleles in 45 different populations (listed across the bottom) from around the world.
Populations are ordered generally as Africa, Europe, East Asia, Americas.
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The Pharmacogenomics JournalCYP2C8, one of the first human cytochrome P450 genes
to be cloned,
27 is well recognized as a significant enzyme in
metabolism of numerous therapeutic drugs. Considerable
interindividual variation in the metabolism of CYP2C8-
specific substrates does exist
12,13 and this variation has been
associated with polymorphism in CYP2C8, which is
reported to be the primary enzyme responsible for the
elimination and detoxification of paclitaxel. Several
association studies have demonstrated a relationship be-
tween CYP2C8 variant alleles, the metabolic index of
paclitaxel
9,11,13,28,29 and drug-related toxicities. In addition,
the ethnic distributions of these polymorphisms had suggested
that variant alleles that affect paclitaxel metabolism are more
common in particular ethnic groups.
6 Extensive ethnic
variation in these polymorphisms is now confirmed in this
study, but this study does not directly address the relevance of
these polymorphisms to paclitaxel metabolism.
Value of haplotypes
It has become clear that the analysis of a single SNP in a
candidate gene may be grossly inadequate in examining
genotype–phenotype relationships. Analysis of haplotypes,
the combinations of SNP alleles on one chromosome, can
show that certain alleles at different SNPs often, or usually,
occur on the same chromosomes in the population at
frequencies greater than expected by chance, that is, there is
LD. Proteins are encoded in cis from each single chromo-
some; so the combination of coding variants on a chromo-
some determines the resulting properties of the enzyme
encoded by that chromosome. In addition, many cis-acting
regulatory sequences can show variation and determine how
much of and in which tissues a protein is synthesized.
Hence, haplotype analysis is an essential method for
detecting associations between sets of genetic variation
and gene function whenever more than a single functional
SNP may be involved. The value of haplotypes is illustrated
by the work of Rodriguiz-Antona et al.
13 who studied 12
SNPs across the CYP2C8 gene in a moderate sample
of 54 unrelated individuals defined loosely only as
‘Caucasians’. They could not find an effect on paclitaxel
metabolism associated with heterozygosity for either the
CYP2C8*399Arg and CYP2C8*139Lys containing haplotype
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Figure 2 CYP2C9–CYP2C8 haplotype frequencies. The frequencies of the 17 common haplotypes of CYP2C8–C9 single nucleotide polymorphisms
(SNPs). The figure illustrates the frequencies of these haplotypes in 45 different populations listed from top to bottom on the left side in the same
order as in Figure 1. The length of each colored bar represents the frequency of the corresponding haplotype in that population. The allelic
compositions for the haplotypes are given in Table 2; the frequencies are in ALFRED. Haplotypes that are rare (less than 5%) in all populations are
combined into a residual class. Note that coding variants can occur in different combinations and as part of different haplotypes.
CYP2C8–C9 haplotype variation
WC Speed et al
286
The Pharmacogenomics Journalor the CYP2C8*264Met containing haplotype. However, a
different haplotype, labeled B in their study, did have
increased 6a-hydroxylation of paclitaxel. This haplotype B
had derived nucleotides in the promoter region, in intron 2
and in intron 7.
Haplotypes in our study
In this study, we genotyped and haplotyped CYP2C8 and
CYP2C9 alleles in a large population cohort representing 45
populations from around the world. This dataset represents
the most comprehensive study of frequencies of multiple
CYP2C8 and CYP2C9 SNPs in diverse populations thus far.
We observed striking allele frequency variation of individual
polymorphisms among different populations (Figure 1; data
in ALFRED). This finding is in line with general expectations
for human polymorphisms and long standing clinical
observation of ethnic differences in response to and toxicity
from various drugs metabolized by the CYP2C subfamily.
The global variation in haplotype frequencies (Figure 2; data
in ALFRED) similarly shows large interpopulation variation.
For example, haplotype G reaches an average frequency of
0.10 in Europe, whereas its frequency averages less than 0.01
in other regions of the world. It is reasonable to hypothesize
that some of these population-specific distributions of
individual alleles and/or haplotypes may have functional
impact, resulting in interindividual and interethnic hetero-
geneity in drug metabolism, response and toxicity.
Linkage disequilibrium between CYP2C9 and CYP2C8
Three of the coding missense variants are especially inter-
esting from a population genetics perspective and have
significant research implications, and potentially clinical
implications, in European populations. The three are
CYP2C9*144Cys, CYP2C8*399Arg and CYP2C8*139Lys.
These three occur in only three haplotypes: G, H and K
(Table 2 and Figure 2). Although CYP2C8*399Arg and
CYP2C8*139Lys are always seen in cis, they occur with the
CYP2C9*144Cys variant in haplotype G and without it in
haplotype K. The CYP2C9*144Cys allele occurs by itself in
haplotype H. Only in the European and Southwest Asian
populations do we see haplotypes G, H and K simulta-
neously present. In these populations on average 90% of
chromosomes with the CYP2C9*144Cys allele also carry
these two CYP2C8 variants (Table 3). Thus, an exploratory
study in Europeans and/or Southwest Asians of association
of the CYP2C9*144Cys allele with a trait (disease risk,
therapy response and others) will usually be simultaneously
studying CYP2C8 variation. Conversely, on average 89% of
chromosomes with either of the two CYP2C8 variants also
carry the CYP2C9*144Cys allele. This strong association
implies that if any of the three relevant SNPs gives a positive
result in a case–control study, it will be difficult to
distinguish any association with CYP2C9 from an associa-
tion with CYP2C8 and vice versa. Given studies of CYP2C8/
CYP2C9 pharmacokinetics of ibuprofen,
29 it is likely that
haplotype effects will be seen for other joint substrates of
CYP2C8 and CYP2C9, such as verapamil, isotretinoin,
retinoic acid, arachidonic acid and fluvastatin.
1,30 Moreover,
given this pattern of LD, there could well be other important
variation yet to be identified, especially on haplotype G.
Other functional variation?
Previous studies of variation at CYP2C8 and CYP2C9 may
not have uncovered the true wealth of African-specific
functional variation. For example, haplotypes B, L and M,
containing the CYP2C8*269Phe allele, reach a combined
average frequency of 0.17 in Africa, whereas occurring at less
than 0.01 in the rest of the world. Thus, it is also clear that
17% of African patients may have a very different drug
response, due to their haplotypes with the variant
CYP2C8*269Phe allele. In addition, at least three other
haplotypes (D, F and O) reach an average frequency of
greater than 0.10 in Africa, but are less frequent, on average,
in Europe and East Asia, where most previous resequencing
efforts have been concentrated. Resequencing a number of
African individuals with these haplotypes may discover
frequent coding variants, which may provide explanations
for pharmacogenomic diversity unexplained by the
Arg139Lys, Met264Ile, Ile269Phe and Lys399Arg poly-
morphisms in CYP2C8 and the Arg144Cys polymorphism
in CYP2C9. As we approach the ability to truly examine each
individual’s DNA sequence to predict optimal therapy, we
will need to know what actual genetic variation exists in the
population to interpret an individual’s DNA sequence.
Table 3 The interdependencies of the CYP2C9*144Lys and
CYP2C8*399Arg plus CYP2C8*139Lys alleles in European and
Southwest Asian populations
Freq (G)/(Freq (G)
+ Freq (H))
Freq (G)/(Freq (G)
+ Freq (K))
Yemenites 0.89 0.80
Druze 0.91 1.00
Samaritans 0.82 1.00
Adygei 0.83 0.83
Chuvash 1.00 1.00
Russia_A 1.00 0.40
Russia_V 0.75 1.00
Ashkenazi 0.83 0.94
Finns 1.00 0.89
Hungarians 1.00 1.00
Danes 0.85 0.92
Irish 1.00 0.92
EuroAmer 0.87 0.91
Median 0.89 0.92
Mean 0.90 0.89
For each population the first column gives the proportion of the CYP2C9*144Lys
chromosomes in the population that also have the CYP2C8*399Arg plus
CYP2C8*139Lys alleles (always seen together) on the same chromosome. The
second column gives the converse: the proportion of the CYP2C8*399Arg
plus CYP2C8*139Lys chromosomes in the population that also have the
CYP2C9*144Lys allele on the same chromosome. The numbers are calculated
from the frequencies of the relevant haplotypes, represented as Freq (G), Freq (H)
and Freq (K).
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efforts to identify additional sequence variation, it is useful
to identify the distinct evolutionary sequences that repre-
sent lineages that may have independently accumulated
variation. To that end we have examined the existing
haplotypes we have identified in conjunction with knowl-
edge of the ancestral sequences. Three segments of this
132kb segment of chromosome 10 show no obligate
crossover products. The 17 common haplotypes can be
explained by a series of historical crossovers among
the different haplotypes of the three segments (Supplemen-
tary Material). In addition to testing multiple populations
for whatever new polymorphic variation is found, we need
to test more existing SNPs in known regulatory regions as
well as those that might have less obvious functional
consequences: synonymous coding SNPs that could affect
mRNA folding and/or mRNA stability as well as intronic
SNPs that could affect splicing or may have regulatory
function. SNPs recently implicated in paxitaxel pharmaco-
kinetics have especially high priority (for example, 13).
Whatever complexity additional SNPs may add to the initial
haplotype frequency data we have presented here, addi-
tional SNPs can only subdivide the haplotypes defined by
the 10 SNPs we have studied and cannot alter the
frequencies of the existing combinations of alleles at the
missense SNPs.
Lack of comparability across studies
The Rodriguiz-Antona et al. study
13 also illustrates a general
problem: the need to consider these loci as haplotypes based
on a common set of polymorphisms with each haplotype
treated as an allele. We are not able to rigorously compare
our 8-SNP haplotypes across CYP2C8 (ignoring the 2 SNPs at
CYP2C9) with the Rodriguiz-Antona et al.
13 12-SNP haplo-
types because only four SNPs were studied in common.
Based on the four SNPs studied in common, their haplotype
B (which shows altered paclitaxel metabolism) falls within a
pool of 10 of our 17 common haplotypes (see Supplemen-
tary Data). This pool of haplotypes has a total frequency
ranging from 68 to 85% among our 10 specific European
samples. An obvious future study for us is to add into our
dataset the SNPs that specifically identified their haplotype
B to allow meaningful comparison of datasets. Similarly,
many other studies of CYP2C8 have used only subsets or
overlapping sets of polymorphisms to define the relevant
haplotypes. We believe that a database of dense marker
coverage of each gene in multiple populations will be
necessary to define what haplotypes are common in
different parts of the world. Such data allow reasonable
inference from a few markers of the actual haplotypes
present in a future study and allow meaningful comparisons
among studies. Our study is an initial step toward such a
database.
We believe this study also provides a basis for systematic
searches for additional functional variation that may occur
at a moderate frequency in one or more regions of the world.
When more SNPs are systematically typed across CYP2C8
and CYP2C9 (and the nearby CYP2C18 and CYP2C19), a
better picture of the population genetic structure of this
region will emerge.
Methods
Markers studied
Using dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/),
the International HapMap Project (www.hapmap.org),
Applied Biosystems’ SNPBrowser (http://marketing.applied
biosystems.com/mk/get/snpb_landing) and the UCSC
Genome Browser (http://genome.ucsc.edu/) we compiled
data on confirmed SNPs, including the more common
functional variants at CYP2C8 and CYP2C9. From this set
we selected 10 SNPs likely to be reasonably heterozygous in
some part of the world, or confirmed to have functional
consequences and frequencies in the polymorphic range,
that is, the frequency of the less common allele was 40.01
(Table 1). Of the 10 SNPs, 5 were coding SNPs (cSNPs), 4 in
CYP2C8 and 1 in CYP2C9. We emphasized SNPs at CYP2C8
but, based on some reports of LD with CYP2C9,
6,23 we
included two SNPs at the 50 end of CYP2C9. The five
noncoding SNPs were chosen to show different frequency
patterns among populations already studied in an attempt
to maximize haplotype diversity with a small number of
SNPs. The final set covered CYP2C8 from just upstream of
the coding sequence to just shy of the last exon. The two
CYP2C9 SNPs extended the total interval covered to just past
the 50 end of CYP2C9. We did not study variants that had
only been reported in single individuals.
Populations studied
We used our resource at Yale University that contains DNA
of more than 2500 unrelated individuals representing
populations from around the world; this resource has been
used for many genetic studies.
31–34 The 45 populations
represented in this study include 10 African (Biaka, Mbuti,
Yoruba, Ibo, Hausa, Chagga, Masai, Sandawe, Ethiopian Jews
and African Americans), 3 Southwest Asian (Yemenite Jews,
Druze and Samaritans), 10 European (Adygei, Chuvash,
Vologda Russians, Archangel Russians, Ashkenazi Jews,
Finns, Hungarians, Danes, Irish and European Americans),
2 Northwest Asian (Komi Zyriane and Khanty), 8 East Asian
(Chinese from San Francisco, Taiwan Han Chinese, Hakka,
Koreans, Japanese, Ami, Atayal and Cambodians), 1 North-
east Siberian (Yakut), 2 from Pacific Islands (Nasioi Melane-
sians and Micronesians), 4 North American (Cheyenne,
Pima from Arizona, Pima from Mexico, Maya) and 4 South
American (Quechua, Ticuna, Rondonia Surui, Karitiana). All
subjects gave informed consent under protocols approved
by the committees governing human subjects research
relevant to each of the population samples. Sample descrip-
tions and sample sizes can be found in ALFRED, the ALlele
FREquency Database (http://alfred.med.yale.edu) and in a
previous publication.
34 We also typed three individuals from
each of five other primate groups: Pan troglodytes, Pan
paniscus, Gorilla gorilla, Pongo pygmaeus and Hylobates sp.
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The Pharmacogenomics JournalMarker typing
All markers were typed using TaqMan assays purchased from
Applied Biosystems; the assay numbers are given in Table 1.
Manufacturer’s protocols were followed, with reaction
volumes reduced to 3ml, run in 384-well plates and read
on an AB9700HT using Applied Biosystems’ SDS (sequence
detection system) software.
Statistical analyses
Genotype and allele frequencies for each individual site
were estimated by simple gene counting, assuming codomi-
nant inheritance with no silent alleles; data were consistent
with that assumption. Hardy–Weinberg ratios were tested by
w
2 and by an ‘exact’ test using 1000 simulations when small
(o5) observed numbers were present for one or more
genotype in a population. Haplotypes were estimated using
PHASE
35 and fastPHASE
36 with subpopulation information.
There were o1% discrepancies in estimation between the
two methods; discrepancies were individually examined.
Differences in estimation of missing data for a SNP were
responsible for all phasing discrepancies, with the data from
PHASE generally being more consistent (fewer rare haplo-
types), so the PHASE haplotypes were used. Genotypes of
individuals were analyzed by HAPLOT
37 for identifying
regions with strong LD, sometimes called ‘LD blocks’ (data
not shown). We have not attempted to relate these
haplotypes to the CYPAlleles nomenclature (www.cypalle-
les.ki.se) because we have not studied all of the SNPs used in
some of the definitions and, as demonstrated here, the
allelic definitions for CYP2C9 are not independent of those
for CYP2C8.
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